Literature DB >> 824723

Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties--outline of toxicological and pharmacokinetic data.

L Julou, J C Guyonnet, R Ducrot, J Fournel, J Pasquet.   

Abstract

Ketoprofen possesses the typical pharmacological properties of non-steroidal anti-inflammatory agents i.e. anti-inflammatory, analgesic and antipyretic activity, as well as antibradykinin activity and ability to inhibit prostaglandin synthesis. Ketoprofen is as potent as indomethacin in the tests for anti-inflammatory and analgesic activity, but its antipyretic and antibradykinin activities and its inhibitory activity against prostaglandin synthesis is respectively 4, 8 and 8 times greater than that of indomethacin. It seems very likely that the pituitary-adrenal axis is not involved in the mechanism of the anti-inflammatory action of ketoprofen, since in the carrageenan abscess test, the compound shows the same activity both in adrenalectomized and in normal rats and, when locally applied to the inflamed area, it is more active than when administered systemically. In the mouse the acute oral toxicity of ketoprofen is about one twentieth that of indomethacin. Like all powerful steroidal or non-steroidal antiinflammatory agents, ketoprofen shows some gastrointestinal toxicity, but its effect is mild and distinctly less than that of indomethacin. Pharmacokinetic studies in the rat, dog and monkey have shown that gastro-intestinal absorption of the drug is rapid and almost complete; the compound and its metabolites are excreted from the body fairly rapidly.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 824723

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  6 in total

1.  A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents.

Authors:  R E Pemberton; L J Strand
Journal:  Dig Dis Sci       Date:  1979-01       Impact factor: 3.199

2.  A therapeutic dose of ketoprofen causes acute gastrointestinal bleeding, erosions, and ulcers in rats.

Authors:  Lisa J Shientag; Suzanne M Wheeler; David S Garlick; Louise S Maranda
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-11       Impact factor: 1.232

3.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.

Authors:  Kyle S Saitta; Carmen Zhang; Kang Kwang Lee; Kazunori Fujimoto; Matthew R Redinbo; Urs A Boelsterli
Journal:  Xenobiotica       Date:  2013-07-05       Impact factor: 1.908

4.  Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay.

Authors:  R A Upton; R L Williams; T W Guentert; J N Buskin; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  A comparison of the carrageenan edema test and ultraviolet light-induced erythema test as predictors of the clinical dose in rheumatoid arthritis.

Authors:  I G Otterness; E H Wiseman; D J Gans
Journal:  Agents Actions       Date:  1979-06

6.  Behavioral Battery for Testing Candidate Analgesics in Mice. I. Validation with Positive and Negative Controls.

Authors:  C M Diester; E J Santos; M J Moerke; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2021-02-23       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.